Physical- and Chemical-Dually ROS-Responsive Nano-in-Gel Platforms with Sequential Release of OX40 Agonist and PD‑1 Inhibitor for Augmented Combination Immunotherapy

• Published in: Nano letters 2023-02, Vol.23 (4), p.1424-1434
• Main Authors: Fu, Yu, Huang, Yulan, Li, Pingrong, Wang, Luyao, Tang, Zhongjie, Liu, Xinlong, Bian, Xufei, Wu, Shuang, Wang, Xiaoyou, Zhu, Biyue, Yu, Yang, Jiang, Jiayun, Li, Chong
• Format: Article
• Language: English
• Subjects: Animals; Gels - chemistry; Immune Checkpoint Inhibitors - pharmacology; Immune Checkpoint Inhibitors - therapeutic use; Immunotherapy - methods; Melanoma - drug therapy; Mice; Nanostructures - chemistry; Nanostructures - therapeutic use; Reactive Oxygen Species; Receptors, OX40 - antagonists & inhibitors; Receptors, OX40 - immunology
• ISSN: 1530-6984; 1530-6992
• DOI: 10.1021/acs.nanolett.2c04767

Combination immunotherapy synergizing the PD-1 blockade with OX40 agonism has become a research hotspot, due to its enormous potential to overcome the restricted clinical objective response suffered by monotherapy. Questions of timing and sequence have been important aspects of immunotherapies when considering immunologic mechanisms; however, most of the time the straightforward additive approach was taken. Herein, our work is the first to investigate an alternative timing of aOX40 and aPD-1 treatment in melanoma-bearing mice, and it demonstrates that sequential administration (aOX40 first, then aPD-1 following) provided superior antitumor benefits than concurrent treatment. Based on that, to further avoid the limits suffered by solution forms, we adopted pharmaceutical technologies to construct an in situ-formed physical- and chemical-dually ROS-responsive nano-in-gel platform to implement sequential and prolonged release of aPD-1 and aOX40. Equipped with these advantages, the as-prepared (aPD-1NCs&aOX40)@Gels elicited augmented combination immunity and achieved great eradication of both primary and distant melanoma tumors in vivo.